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ABSTRACT
Allogeneic bone marrow transplantation (BMT) remains the primary treatment for many hematologic malig-
nancies but has had limited success against solid tumors. The antitumor activity of this treatment approach
involves the tumoricidal activity of chemoradiation and the additive graft-versus-tumor activity of donor T
cells. However, even with current protocols, some tumors develop resistance and become unresponsive to
current therapeutic regimens. To address the problem of resistance and lack of solid tumor activity in
allogeneic BMT, we undertook experiments to determine whether the graft-versus-tumor activity of donor T
cells could be enhanced in the period immediately after allogeneic BMTwith tumor lysate-pulsed dendritic cell
(DC) vaccines. Using the B16 melanoma model, we found that the treatment of 6-day tumors with allogeneic
BMT and 3 weekly vaccinations of tumor lysate-pulsed DCs starting 3 days after BMT had a significant effect
on the growth of murine flank melanomas. This effect was tumor specific and occurred in the absence of full
immune reconstitution as measured by donor T cell engraftment and cytotoxic T lymphocyte activity. In
addition, DC vaccinations did not appear to exacerbate graft-versus-host disease. These experiments support
the feasibility of DC vaccine strategies in the setting of allogeneic BMT.
© 2006 American Society for Blood and Marrow Transplantation
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ENTRODUCTION
The relapse of hematologic malignancies after
one marrow transplantation (BMT) remains a signif-
cant clinical problem because of the frequent lack of
esponse of resistant residual disease to standard che-
oradiation protocols [1]. In addition, allogeneic
MT strategies have had only limited success in treat-
ng solid tumor malignancies [2-4]. An improvement
n clinical outcomes will likely require new and inno-
ative adjuncts to current treatment regimens.
Current intensive chemoradiation protocols are
hought to generate most of the antitumor effects seen
n autologous BMT [1], whereas the additive graft-
ersus-tumor (GVT) response mediated by donor T
ells is believed to be important in allogeneic BMT m
0105]. It is thought that the same factors that are respon-
ible for GVT activity also play a role in graft-
ersus-host-disease (GVHD) [6]. What remains un-
lear, however, is whether or not the donor T cell
opulations involved in GVT activity can be ex-
anded in the setting of incomplete immune recon-
titution with current immunotherapeutic strategies
nd whether this can be accomplished without exac-
rbating GVHD.
The ability to use immunotherapeutic approaches
n the post-BMT setting is thought to be dependent
n functional immune recovery [7-10] and the exact
iming of this process is unclear. Evidence exists, how-
ver, that immunization after BMT may be feasible.
ffective immunization of children against measles,
umps, and rubella [11] and vaccinations against po-
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Antitumor Effect of Early Vaccination with TL-Pulsed DCs after Allogeneic BMT 1011io and hepatitis B have been effective when given in
he post-transplantation setting [12,13]. In addition,
mmunization of a human donor with a myeloma-
ssociated paraprotein conferred tumor-speciﬁc im-
unity to a recipient of an allogeneic bone marrow
ransplant [14]. More recently, several immunthera-
eutic strategies in mice have been successful in the
etting of allogeneic BMT. In particular, tumor cell
accines after BMT have been shown to elicit speciﬁc
ntitumor responses without exacerbating GVHD
7,10].
Another immunotherapeutic approach is the use
f dendritic cells (DCs). DCs are potent antigen-
resenting cells with the ability to stimulate primary
nd secondary T and B cell responses [15] and have
een used as antitumor vaccines in preclinical and
linical studies with encouraging results [16,17]. DCs
re thought to be the primary cells that sensitize naive
cells to an initial antigen exposure. Although hu-
oral and cellular effector pathways can contribute to
umor lysis, effector mechanisms involving CD8 cy-
otoxic T lymphocytes (CTLs) are thought to be cen-
ral to the ability to recognize and kill tumor cells [18].
n addition, evidence exists that DCs can directly elicit
atural killer cell functions, which can further facili-
ate tumor destruction [19]. The potency of DC an-
igen presentation and the subsequent immune re-
ponse makes it an ideal approach for the generation
f an antitumor immune response in early T cell
econstitution.
To investigate whether early DC vaccination
trategies can be used in the setting of allogeneic
MT, we examined the ability of early vaccination
ith tumor lysate (TL)-pulsed DCs soon after BMT
o elicit an antitumor effect in mice with established
umor (treatment model). In a tumor protection
odel, we also tested the ability of early vaccination
ith TL-pulsed DCs after BMT to elicit protection in
aive mice that were subsequently challenged with
umor. Our ﬁndings suggest that early vaccination
fter BMT before full immune reconstitution with
L-pulsed DCs can generate an antitumor effect in
nimals with established tumor, but an inability to
onfer protection to naive mice challenged with tumor
fter TL-pulsed DC vaccination.
ETHODS
ice
Six- to eight-week-old female C57BL/6 (B6, H-2b,
y 9.1) recipient mice and C.B10-H2b/LilMcdJ
B10, H-2b, Ly 9.1) donor mice were obtained from
he Jackson Laboratory (Bar Harbor, Me).The con-
enic MHC locus of the B10 mice was derived from
train C57BL/10J (H-2b), whereas most of the re-
aining loci were of the background strain BALB/ bLilMcdJ (H-2d). Thus, the bone marrow cells de-
ived from the donor B10 mice were matched for
ajor alloantigens, but mismatched for many of the
inor alloantigens. C.10-H2b/LilMcdJ (H-2b) mice
o not reject B16 tumor, however; coat color and
any other minor alloantigens differ from those in
he recipient animal and may play a role in clinical
esponse to vaccines in the setting of BMT. Mice were
oused in microisolator cages and fed autoclaved
how and acidiﬁed water. The experimental protocol
as reviewed and approved by the University Com-
ittee on Use and Care of Animals at the University
f Michigan.
edia and Cytokines
Complete medium (CM) consisted of RPMI 1640
ith 10% heat-inactivated fetal calf serum, 0.1 mM
onessential amino acids, 1 M sodium pyruvate, 2
M fresh l-glutamine, 100 U/mL penicillin, 50
g/mL gentamicin, 0.5 g/mL fungizone, and 5 
05 M 2-mercaptoethanol. Recombinant murine
ranulocyte-macrophage colony-stimulating factor
GM-CSF; speciﬁc activity 5  106 U/mg) was
btained from Immunex Corp (Seattle, Wash) and
ecombinant murine interleukin (IL)-4 (2.8  108
/mg) was obtained from Schering-Plough Pharma-
eutical Research Institute (Kennilworth, NJ). IL-2
as provided by Chiron (Emeryville, Calif) and had a
peciﬁc activity of 18  106 IU/mg protein.
umor Cell Lines
B16-BL6 (B16) is derived from B6 mice and is a
oorly immunogenic melanoma of spontaneous origin
20]. Tumors were cultured in vivo and used before
he ﬁfth passage. For vaccination experiments without
one marrow transplant, 5  104 B16 tumor cells
treatment model) and 1  105 B16 tumor cells (pro-
ection model) were injected subcutaneously into the
ight ﬂank of B6 recipient mice. For vaccination ex-
eriments with bone marrow transplant, 2  105 B16
umor cells (treatment model) and 1  105 B16 tumor
ells (protection model) were injected subcutaneously
nto the right ﬂank of B6 recipient mice. Animals with
umors that became ulcerated, caused impaired mo-
ility, or in the judgment of the animal care techni-
ians or principal investigator caused unnecessary
tress or discomfort to the animal were euthanized
ith carbon dioxide narcosis.
llogeneic BMT
C57BL/6 mice with established 6-day tumor
treatment model) and mice without tumor (protec-
ion model) received 10 Gy total body irradiation
TBI; cesium 137 source), split into 2 doses and sep-
rated by 3 hours. B10 donor erythrocyte-depleted
one marrow cells, 1  107, ﬂushed from the femurs
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J. S. Moyer et al.1012nd tibias were injected intravenously in a volume of
.5 mL Hank balanced salt solution (HBSS) on the
ay of TBI. Mice were monitored daily for signs of
linical GVHD by looking for weight loss, posture
hanges, decreased activity, fur loss and texture
hanges, and impairment of skin integrity.
eneration of Bone Marrow-Derived DCs
Erythrocyte-depleted bone marrow cells ﬂushed
rom the femurs and tibias of B10 mice were cultured
n 10 ng/mL GM-CSF and 10 ng/mL IL-4 at 1  106
ells/mL in CM. On day 3, fresh cytokines were
dded, and nonadherent cells were harvested on day 5
y gentle pipeting. DCs were enriched by density
entrifugation over 14.5% (w/v) metrizamide (Sigma,
t Louis, Mo) [21]. The low-density population (buffy
oat) was washed several times with CM. The result-
ng DC population had the typical morphologic char-
cteristics of DCs and was 80% positive for coex-
ression of MHC II and CD86 (data not shown). DCs
t 1  106/mL were pulsed in CM for 18 hours with
16 TL prepared as previously described [22] or 10
g/mL Trp2 (180-188; Research Genetics, Hunts-
ille, Ala). Trp-2 is a melanoma tumor-associated an-
igen and has been shown in some studies to have
ntitumor effects [23]. Unpulsed DCs at 1  106 were
ncubated overnight in 10 ng/mL GM-CSF and 10
g/mL IL-4. DCs were subsequently detached from
ulture plates with 3 mM ethylenediaminetetraacetic
cid, washed 2 times in HBSS, resuspended in HBSS
o a concentration of 1  107 DC/mL, and irradiated
ith 20 Gy before use. DCs at 1  106 (0.1 mL) were
njected subcutaneously into the left inguinal region
ontralateral to the tumor on days 3, 10, and 17 after
MT. In protection experiments performed with
L-2, 60 000 IU IL-2 was given twice daily intraperi-
oneally on the day of DC vaccination and for 3
onsecutive days thereafter. All experiments were per-
ormed with 5 mice per treatment group and were
epeated at least once with similar ﬁndings.
luorescence-Activated Cell Sorting Analysis
Fluorescein isothiocyanate-conjugated monoclo-
al antibodies to Ly 9.1, phycoerythrin-conjugated
onoclonal antibodies to CD25, CD69, and CD62L,
nd cychrome-conjugated monoclonal antibodies to
D4 and CD8 were purchased from PharMingen
San Diego, Calif). Splenocytes were obtained by mac-
rating the spleens between 2 frosted glass slides,
ollowed by lysis of erythrocytes with ACK lysing
uffer. Splenocytes were ﬁrst incubated with rat anti-
ouse FcR monoclonal antibodies for 30 minutes at
°C to block nonspeciﬁc FcR binding of antibodies
nd then stained with the appropriate monoclonal
ntibody for 30 minutes at 4°C. Cells were then
ashed with 1% bovine serum albumin in phosphate Cuffered saline (PBS), ﬁxed with 1% paraformaldehyde
n PBS, and analyzed by FACScaliber (Becton Dickin-
on, San Jose, Calif). Ten thousand live events were
nalyzed. Donor T cell engraftment was determined by
he percentages of Ly 9.1 cells among CD4 and
D8 cells from pooled samples of 2 mice per group.
hromium 51 Release Assays
Pooled effector splenocytes of 3 mice from the
arious treatment groups were cultured in 24-well
lates at 1  106 cells/mL in CM. Splenocytes were
timulated for 4-5 days with 1  105 irradiated B16
umor cells, 5  104 irradiated Trp2-pulsed DCs, or
 104 irradiated TL-pulsed DCs. Lymphocyte-ac-
ivated killer cells were generated by culturing spleno-
ytes for 5 days in 6000 IU/mL IL-2. Effector cells
ere harvested and plated in triplicate in various ef-
ector:target ratios with 5  104 interferon- (IFN-
)-treated B16 targets labeled with chromium 51
51Cr). Targets were prepared by suspending 1  106
16 tumor cells in 1 mL CM with 200 Ci 51Cr
NEN Life Sciences Products, Boston, Mass) for 60
inutes. Targets were washed twice with HBSS and
esuspended in 2 mL CM and 100 L was pipetted
nto 96-well plates. Plated cells were incubated with
ffector T cells for 4 hours at 37°C and the supernan-
ants were absorbed into SCS harvesting frames (Ska-
ron, Lier, Norway) and counted on a Cobra II Auto-
ammaCounter (Packard Biosciences, Downers Grove,
ll). Percentage lysis was calculated as 100  [(experi-
ental cpm  spontaneous cpm)/(maximum cpm  spon-
aneous cpm)]. Spontaneous release was always 30%
f the maximal release and typically 20%.
uantitation of IFN- in Vaccine Primed
ymph Node
The left inguinal lymph node, the vaccine primed
ymph node (VPLN), was removed from mice in the
arious treatment groups and a single-cell suspension
as generated by lysing the capsule of the lymph node
etween 2 frosted microscope slides. VPLNs from 2
ice per group were pooled for these experiments. In
ddition, 5  105 VPLN cells in 1 mL CM were
lated in 12-well plates for 48 hours alone or with 5
04 irradiated B16 tumor cells. Supernatants were
arvested and assayed for IFN- by enzyme-linked
mmunosorbent assay (PharMingen).
tatistical Analysis
For comparison of treatment groups, 1-way anal-
sis of variance (followed by Newman-Keuls post hoc
est) was performed. All statistical analysis was per-
ormed with GraphPad Prism software (San Diego,
A). Statistical signiﬁcance was deﬁned as P  .05.
RI
V
A
a
v
m
t
D
(
B
e
n
t
c
p
T
H
a
o
s
r
F
m
w
s
t
(
Antitumor Effect of Early Vaccination with TL-Pulsed DCs after Allogeneic BMT 1013ESULTS
n the Non-BMT Setting, TL-Pulsed DC
accination in a Treatment Model Has No
ntitumor Effects
Experiments were performed in the absence of
llogeneic BMT to assess the effect of TL-pulsed DC
accinations on tumor progression in a treatment
odel and a protection model.
In the treatment model, B6 mice with 7-day subcu-
aneous tumor were treated with PBS alone, unpulsed
Cs, Trp2 (180-188)-pulsed DCs, and TL-pulsed DCs
Figure 1A). DCs were derived from the bone marrow of
6 mice. There were no statistically signiﬁcant differ-
nces between groups in the treatment model.
igure 1. TL-pulsed DC vaccination alone does not have a signiﬁca
ice were treated with 1  106 BL6 DC delivered subcutaneously
ere treated with PBS (circles), unpulsed DC (diamonds), Trp2 (18
tatistically signiﬁcant differences between treatment groups (P  .0
hen challenged on day 4 after the ﬁnal vaccination with 1  105 B
triangles), or TL-pulsed DC (squares). There were no statistically signiﬁIn a protection model (Figure 1B), mice vacci-
ated with TL-pulsed DCs had a trend toward smaller
umors, but this was not statistically signiﬁcant and
onsistent across several experiments.
No mice were tumor free in the treatment or
rotection model experiments.
L-Pulsed DC Vaccination in a Treatment Model
as Antitumor Effects When Given Early
fter BMT
Experiments were performed to determine whether
r not early vaccination with DC vaccines in the
etting of allogeneic BMT could elicit an antitumor
esponse against an established tumor.
tumor effect . A, 7-day subcutaneous B16 tumors (5  104) in BL6
contralateral ﬂank on days 7 and 11 after tumor inoculation. Mice
pulsed DC (triangles), or TL-pulsed DC (squares). There were no
ice were immunized with 3 weekly DC vaccinations (1  106) and
or cells. Mice were vaccinated with PBS (diamonds), unpulsed DCnt anti
to the
0-188)-
5). B, M
16 tumcant differences between treatment groups (P  .05).
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J. S. Moyer et al.1014Donor bone marrow was obtained from congenic
10 mice (H-2b, Ly 9.1), mice who have the coat
olor and minor alloantigens of BalbC (H-2d) mice
ut whose MHC is that of B6 mice. Thus, bone
arrow that was major alloantigen histocompatible
ut mismatched at many of the minor alloantigens was
ransplanted into C57/BL6 (H-2b, Ly 9.1) mice.
We ﬁrst determined the optimal timing of trans-
lantation after the establishment of tumor. TBI and
llogeneic BMT were performed on 3-, 6-, and 9-day
16 ﬂank tumors. Treatment of 6-day tumors with
BI/BMT generated a tumor growth curve after 30
ays that was comparable to that seen in immunocom-
etent syngeneic mice (data not shown).
Subsequently, 6-day B16 tumors in B6 mice were
reated with TBI/BMT. Mice were treated with TBI/
MT alone or with 3 weekly injections of unpulsed
Cs, Trp2 (180-188)-pulsed DCs, or TL-pulsed
Cs, starting on day 3 after BMT. Figure 2 demon-
trates that mice treated with TL-pulsed DCs after
llogeneic BMT had a statistically signiﬁcant, slower
umor progression (P  .0001) when compared with
ice treated with allogeneic BMT alone, unpulsed
Cs, or Trp2-pulsed DCs. No animals were found to
e tumor free after TL-pulsed DC vaccinations.
hese experiments were performed twice with similar
esults.
Experiments were also performed to determine
hether or not early vaccination with DCs after allo-
eneic BMT would generate protective immunity
hen animals were subsequently challenged with tu-
or.
B6 mice without tumor underwent TBI/BMT
igure 2. Early treatment after allogeneic (allo) BMT with TL-puls
ere treated with 1000 rads split-dose TBI and allogeneic BMT
ubcutaneously in the ﬂank contralateral to the tumor on days 3, 10
quares), unpulsed DC (open squares), Trp2 (180-188)-pulsed DC (
o be tumor free after TL-pulsed DC vaccinations. This experiment waslone or 3 weekly injections of unpulsed DCs or TL-
ulsed DCs, starting on day 3 after BMT (Figure 3). A
econd series of mice was given intraperitoneal IL-2
njections the day of DC vaccinations and for 3 con-
ecutive days thereafter in an attempt to expand tumor
eactive T cell populations (data not shown). One
eek after the ﬁnal DC vaccination and 24 days after
MT, mice were challenged with 1  105 B16 tumor
ells in the ﬂank contralateral to the vaccination site.
here were no statistically signiﬁcant differences in
he rate of tumor growth in all groups tested in the
umor protection model (P  .05). These experiments
ere repeated with consistent ﬁndings.
ntitumor Effect Occurs without Full
Cell Reconstitution
To assess the degree of donor T cell engraftment
4 days after allogeneic BMT of B6 mice, immuno-
henotyping was performed on splenocytes from mice
reated with TBI/BMT alone or with unpulsed DCs,
rp2-pulsed DCs, or TL-pulsed DCs. T cells from
onor splenocytes were 100% Ly 9.1, whereas re-
ipient T cells were 100% Ly 9.1.
These experiments revealed that in the treatment
odel 24 days after BMT,50% of CD4 and CD8
cells in recipient B6 spleens were donor derived (Ly
.1; Figure 4). Thus, even in the absence of full
mmune reconstitution, animals treated with TL-
ulsed DCs in the treatment model could generate an
ffective antitumor response.
Reconstitution of donor-derived CD8 T cells
as consistently greater than that of donor-derived
D4 T cells in all treatment groups 24 days after
s has antitumor effects. Six-day subcutaneous B16 tumors (1  105)
107 cells). Three weekly doses of 1  106 DCs were delivered
7 after BMT. Mice were treated with allogeneic BMT alone (solid
s), or TL-pulsed DC (circles). *P  .0001. No animals were founded DC
(1 
, and 1
triangleperformed twice with consistent results.
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Antitumor Effect of Early Vaccination with TL-Pulsed DCs after Allogeneic BMT 1015MT. This ﬁnding was present in the treatment and
rotection models (Figures 4 and 5). The addition of
endritic cell vaccinations in the setting of allogeneic
MT increased the total number of CD4 T cells in
he spleen compared with allogeneic BMT alone;
owever, the numbers of donor-derived CD4 T cells
as lower. Interestingly, the percentage of donor
D4 T cells and that of donor CD4/CD8 ratio for
L-pulsed DC vaccination in the treatment model
ere statistically lower than that for the control (allo-
eneic BMT alone).
Because of tumor progression, only the protection
odel was studied at day 38 after BMT (Figure 5).
igure 3. Early immunization after allogeneic BMT does not conf
plit-dose TBI and allogeneic BMT (1  107 cells). Mice were imm
MT and then challenged on day 7 (day 24 after BMT) after the ﬁ
BS (solid squares), unpulsed DC (open squares), or TL-pulsed
reatment groups (P  .05).
igure 4.Donor-derived (Ly 9.1) T cell engraftment 24 days after
MT in the treatment model. Splenocytes from recipient mice
reated with the various DC regimens were analyzed for the pres-
nce of the Ly 9.1 marker present in 100% of donor T cells. Resultsrre from pooled samples from 2 mice. *P  .05 versus BMT alone.hese data demonstrate that the numbers of donor-
erived CD4T cells continue to increase to numbers
imilar to those of donor-derived CD8 T cells at 38
ays after BMT. In addition, no meaningful differ-
nces were found in the protection model between
onor-derived CD4 and CD8 T cells when com-
ared with controls.
There were also no differences among treatment
roups for markers of early T cell activation (CD25),
ery early T cell activation (CD69), and effector/
emory T cells (CD62L) that could explain the an-
itumor effects of the TL-pulsed DC regimen (data
ot shown).
ull Reconstitution Not Necessary for
FN- Response
To determine if early TL-pulsed DC vaccinations
fter allogeneic BMT could generate a speciﬁc anti-
umor response, in vitro cytotoxicity assays were per-
ormed 24 days after BMT in the treatment model.
plenocytes from mice treated with BMT alone or
ith DC vaccinations were stimulated in vitro with
16 tumor, Trp2-pulsed DCs, or TL-pulsed DCs and
ested for their ability to lyse B16 tumor cells (Figure
). Based on these results, there did not appear to be
signiﬁcant level of cytolytic immune response 24
ays after BMT, suggesting an inability to generate an
ffective immune response.
To further assess the level of functional immune
ction from tumor challenge. B6 mice were treated with 1000 rads
d with 3 weekly DC vaccinations (1  106) starting on day 3 after
cination with 1  105 B16 tumor cells. Mice were vaccinated with
rcles). There were no statistically signiﬁcant differences betweener prote
unize
nal vac
DC (cieconstitution, we examined the ability of lympho-
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J. S. Moyer et al.1016ytes from lymph nodes draining the DC vaccination
VPLN) site to elicit IFN- production. VPLNs from
ice treated with BMT alone or with DC vaccina-
igure 5.Donor-derived (Ly 9.1) T cell engraftment 24 and 38 days
fter BMT in the protection model. Splenocytes from recipient mice
reated with the various DC regimens were analyzed for the presence
f the Ly 9.1 marker present in 100% of donor T cells. Results are
rom pooled samples from 2 mice. *P  .05 versus BMT alone.
igure 6. Absence of signiﬁcant cytolytic immune response 24 days
rom 3 mice treated with allogeneic (allo) BMT alone or with allog
ays with 2  104 irradiated, IFN--treated B16 cells or with
ymphocyte-activated killer (LAK) cells were generated by culturin
sed as targets in the chromium release assay at an effector:target ratio ofions were cultured alone or with B16 tumor cells for
8 hours. Supernatants were analyzed and quantitated
or the presence of IFN- (Table 1). VPLNs from
ice treated with TL-pulsed DCs had an elevated
aseline level of IFN- secretion that was signiﬁcantly
ncreased when cocultured with B16 tumor cells. This
s in contrast to the VPLNs from mice treated with
npulsed DCs or BMT alone, which did not demon-
trate a signiﬁcant increase in IFN- production in the
resence of tumor.
Together, these results suggest that, even in the
bsence of a signiﬁcant cytolytic response early in the
ourse of T cell reconstitution, TL-pulsed DC vacci-
ations can still elicit a speciﬁc IFN- response that is
orrelated with in vivo antitumor effects.
L-Pulsed DC Vaccination Does Not Exacerbate
VHD in Allogeneic BMT
Recipients undergoing allogeneic BMT alone or
MT and DC vaccinations did not develop signs of
cute GVHD during the time course of the experi-
T in the treatment model. Splenocytes were harvested and pooled
MT and TL-pulsed DCs. T cells (2  105) were stimulated for 5
104 irradiated Trp2 (180-188)-pulsed DCs or TL-pulsed DCs.
ocytes for 5 days in 6000 IU/mL IL-2.51Cr-labeled B16 cells wereafter BM
eneic B
2 
g splen10:1.
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Antitumor Effect of Early Vaccination with TL-Pulsed DCs after Allogeneic BMT 1017ent as evidenced by weight loss, posture changes,
ecreased activity, fur loss, and impairment of skin
ntegrity. In addition, recipient mice without tumor
reated with 3 weekly doses of TL-pulsed DCs were
live at 150 days and without evidence of GVHD.
ISCUSSION
These experiments tested the hypothesis that early
accination with TL-pulsed DCs in the setting of
llogeneic BMT could produce speciﬁc antitumor ef-
ects without worsening GVHD. Three weekly vacci-
ations of TL-pulsed DCs starting 3 days after BMT
licited a signiﬁcant antitumor response against estab-
ished B16 tumors that was associated with elevated
evels of IFN- production from peripheral blood
ononuclear cells in the TL-pulsed DC VPLN (Fig-
re 2). In vitro exposure of TL-pulsed VPLN to B16
umor generated a tumor-speciﬁc elevation in IFN-
roduction (Table 1) in the face of incomplete T cell
econstitution and impaired cytotoxic immune re-
ponse as measured by 51Cr-release assays. In addi-
ion, DC vaccinations after allogeneic BMT did not
ppear to worsen GVHD. Together, these results
upport the feasibility of early DC vaccination strate-
ies in conjunction with allogeneic BMT.
It has been reported that immune reconstitution is
ritical for effective antitumor vaccination and that T
ell recovery is correlated with clinical vaccine efﬁcacy
7,8,24]. What is uncertain, however, is the degree to
hich T cell recovery is achieved with vaccine efﬁ-
acy.
Although some studies have suggested that CD4
nd CD8 cells are necessary for vaccine efﬁcacy [7],
thers have reported that only CD8 cells and natural
iller cells are necessary [25,26]. Our studies demon-
trate that the percent reconstitution of donor-derived
D8 cells is consistently greater than that of CD4
ells (Figures 4 and 5) in the early period (24 days)
fter allogeneic BMT in the treatment and protection
odels. At least in the protection model, by 38 days
fter BMT, the percent donor-derived CD4 T cells
ore closely approximates the percent donor-derived
D8 T cells. In the treatment model experiments,
ur studies suggest that even when only approximately
0% of donor CD8 T cell reconstitution is present,
n effective and speciﬁc antitumor effect is possible
ith TL-pulsed DC vaccinations.
The ﬁndings in the treatment model are in con-
rast to those seen in the protection model, where
arly vaccination did not prevent tumor growth when
ice were subsequently challenged with tumor. The
nly difference between these 2 experimental ap-
roaches was the presence of 6-day tumor during early
econstitution in the treatment model. In the period
mmediately after allogeneic BMT, the presence of †nﬂammatory cytokines and the constant antigen stim-
lation found in animals with established tumors may
e necessary to elicit an effective immune response. In
ddition, the process of homeostatic proliferation may
lay a pivotal role in these ﬁndings. The presence of
arge amounts of deﬁned antigens through DC vacci-
ation and the presence of subcutaneous tumor likely
esult in a preferential expansion of T cell clones with
ncreased afﬁnity to relevant tumor antigens. Our data
ould suggest that TL-pulsed DC vaccination alone
ithout the presence of a tumor burden does not
rovide sufﬁcient tumor antigen stimulation to gen-
rate a clinically relevant antitumor effect.
In addition, the different ﬁndings in these 2 mod-
ls may center around the pivotal role of CD4T cells
n the protection model. Hung et al [27] investigated
he relative importance of CD4 and CD8 T cells in
ouse tumor protection experiments and discovered
hat a signiﬁcant fraction of CD8 knockout, but not of
D4 knockout, animals were able to successfully resist
umor challenge, indicating that in the protection
odel the observed protective effects relied on CD4
cell-mediated effector mechanisms. The lack of a
igniﬁcant effect of IL-2 in the protection model is
lso consistent with the role of CD4 T cells in the
eneration of protective immunity. Strome et al [28]
emonstrated that rejection of IL-2-secreting tumors
as dependent on the presence of CD4 T cells in a
rotection model. Thus, the relative decrease in do-
or-derived CD4 T cell in the period immediately
fter BMT may have a deleterious effect on the estab-
ishment of a signiﬁcant memory T cell response that
ould be necessary in the protection model. This is in
ontrast to the proinﬂammatory environment seen
mmediately after BMT, where the relative impor-
ance of CD8 T cells may be more analogous to the
D8 CTL-responses against acute disease-causing
ytopathic viruses that are relatively independent of
D4 T cell activity [29].
The theoretical risk of GVHD exacerbation was
f concern in the design of these experiments because
able 1. Presence of a Tumor-Speciﬁc IFN- Response in the VPLN
f Mice Treated with TL-Pulsed DCs Early in the Post-BMT Period*
Treatment Groups
VPLN alone
(pg/mL)
VPLN  B16
(pg/mL)
llogeneic BMT alone 0 0
llogeneic BMT  unpulsed-DC 693  101 1489  409
llogeneic BMT  TL-pulsed DC 8226  255 17094  374†
Lymphocytes, 5  105, from VPLNs of the various treatment
groups were cultured alone or with 5  104 irradiated B16
cells for 48 hours. Supernatants were harvested and tested by
enzyme-linked immunosorbent assay for the presence of
IFN- 24 days after BMT. Numbers are presented in pico-
grams per milliliter and represent a pooled sample from 2
mice per group.P  .05 versus VPLN alone.
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J. S. Moyer et al.1018f the priming of T cells with DCs that had been
ulsed with B16 TL (syngeneic for C57/BL6 mice)
ould potentially contain antigens that were also
resent on recipient C57/BL6 tissues. However, our
esults demonstrated that no clinically evident acute
VHD was present in the treatment or protection
odel. In addition, animals in the protection arm of
he experiments without tumor were noted to have no
igns of GVHD 150 days after BMT. These ﬁnding
re consistent with other immunotherapeutic strate-
ies in the allogeneic BMT setting, where tumor vac-
ines did not exacerbate GVHD [9,10]. These ﬁnd-
ngs support the notion that naive donor-derived T
ells may eventually become unresponsive to domi-
ant antigens that are targets for GVHD, whereas the
ntitumor immune response is directed against tumor
ntigens or nonimmunodominant antigens.
Our results suggest that early vaccinations with
L-pulsed DCs may be feasible in the period imme-
iately after allogeneic BMT. We have shown that
peciﬁc antitumor responses are present even in ab-
ence of full immune reconstitution and functional
TL assay activity. However, the antitumor responses
ith TL-pulsed DC vaccines did not result in com-
lete elimination of tumor in this model. This ﬁnding
uggests that the magnitude of T cell response is
nsufﬁcient to cure completely the animals of estab-
ished tumor. Perhaps using a more antigenic tumor
ntigen rather than TL or combining this DC vaccine
ith adoptive immunotherapy strategies could in-
rease the magnitude of the T cell response and result
n complete elimination of tumor. Alternatively, the
urrent vaccine strategy could be used as an adjuvant
herapy in patients with minimal disease, where a less
igorous T cell response may provide greater thera-
eutic utility. Thus, the potential to immunize with
C-based vaccinations in the setting of allogeneic
MT could potentially improve clinical outcomes in
hose individuals at high risk of relapse after chemoir-
adiation and serve as an important adjunct to evolv-
ng studies of allogeneic BMT in solid tumor malig-
ancies.
EFERENCES
1. Armitage JO. Bone marrow transplantation. N Engl J Med.
1994;330:827-838.
2. Barrett J, Childs R. Non-myeloablative stem cell transplants.
Br J Haematol. 2000;111:6-17.
3. Barrett J, Childs R. The beneﬁts of an alloresponse: graft-
versus-tumor. J Hematother Stem Cell Res. 2000;9:347-354.
4. Childs R, Chernoff A, Contentin N, et al. Regression of met-
astatic renal-cell carcinoma after nonmyeloablative allogeneic
peripheral-blood stem-cell transplantation. N Engl J Med. 2000;
343:750-758.
5. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med.
1991;324:667-674.6. Ferrara JL. Pathogenesis of acute graft-versus-host disease:
cytokines and cellular effectors. J Hematother Stem Cell Res.
2000;9:299-306.
7. Teshima T, Mach N, Hill GR, et al. Tumor cell vaccine elicits
potent antitumor immunity after allogeneic T-cell-depleted
bone marrow transplantation. Cancer Res. 2001;61:162-171.
8. Anderson LD Jr, Petropoulos D, Everse LA, Mullen CA. En-
hancement of graft-versus-tumor activity and graft-versus-host
disease by pretransplant immunization of allogeneic bone mar-
row donors with a recipient-derived tumor cell vaccine. Cancer
Res. 1999;59:1525-1530.
9. Anderson LD Jr, Mori S, Mann S, Savary CA, Mullen CA.
Pretransplant tumor antigen-speciﬁc immunization of alloge-
neic bone marrow transplant donors enhances graft-versus-
tumor activity without exacerbation of graft-versus-host dis-
ease. Cancer Res. 2000;60:5797-5802.
0. Anderson LD Jr, Savary CA, Mullen CA. Immunization of
allogeneic bone marrow transplant recipients with tumor cell
vaccines enhances graft-versus-tumor activity without exacer-
bating graft-versus-host disease. Blood. 2000;95:2426-2433.
1. King SM, Saunders EF, Petric M, Gold R. Response to mea-
sles, mumps and rubella vaccine in paediatric bone marrow
transplant recipients. Bone Marrow Transplant. 1996;17:633-
636.
2. Ljungman P, Duraj V, Magnius L. Response to immunization
against polio after allogeneic marrow transplantation. Bone
Marrow Transplant. 1991;7:89-93.
3. Li VS, Di Gregorio F, Romeo MA, et al. Immune status and the
immune response to hepatitis B virus vaccine in thalassemic
patients after allogeneic bone marrow transplantation. Bone
Marrow Transplant. 1997;19:157-160.
4. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma
idiotype-speciﬁc immunity from an actively immunised marrow
donor. Lancet. 1995;345:1016-1020.
5. Banchereau J, Steinman RM. Dendritic cells and the control of
immunity. Nature. 1998;392:245-252.
6. Geiger J, Hutchinson R, Hohenkirk L, McKenna E, Chang A,
Mule J. Treatment of solid tumours in children with tumour-
lysate-pulsed dendritic cells. Lancet. 2000;356:1163-1165.
7. Timmerman JM, Levy R. Dendritic cell vaccines for cancer
immunotherapy. Annu Rev Med. 1999;50:507-529.
8. Fong L, Engleman EG. Dendritic cells in cancer immunother-
apy. Annu Rev Immunol. 2000;18:245-273.
9. Fernandez NC, Lozier A, Flament C, et al. Dendritic cells
directly trigger NK cell functions: cross-talk relevant in innate
anti-tumor immune responses in vivo. Nat Med. 1999;5:
405-411.
0. Fidler IJ. Biological behavior of malignant melanoma cells
correlated to their survival in vivo. Cancer Res. 1975;35:218-224.
1. Fields RC, Osterholzer JJ, Fuller JA, Thomas EK, Geraghty PJ,
Mule JJ. Comparative analysis of murine dendritic cells derived
from spleen and bone marrow. J Immunother. 1998;21:323-339.
2. Shimizu K, Fields RC, Giedlin M, Mule JJ. Systemic adminis-
tration of interleukin 2 enhances the therapeutic efﬁcacy of
dendritic cell-based tumor vaccines. Proc Natl Acad Sci USA.
1999;96:2268-2273.
3. Bloom MB, Perry-Lalley D, Robbins PF, et al. Identiﬁcation of
tyrosinase-related protein 2 as a tumor rejection antigen for the
B16 melanoma. J Exp Med. 1997;185:453-459.
4. Borrello I, Sotomayor EM, Rattis FM, Cooke SK, Gu L,
Levitsky HI. Sustaining the graft-versus-tumor effect through
posttransplant immunization with granulocyte-macrophage
22
2
2
2
Antitumor Effect of Early Vaccination with TL-Pulsed DCs after Allogeneic BMT 1019colony-stimulating factor (GM-CSF)-producing tumor
vaccines. Blood. 2000;95:3011-3019.
5. van Elsas A, Hurwitz AA, Allison JP. Combination immuno-
therapy of B16 melanoma using anti-cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4) and granulocyte/macrophage
colony-stimulating factor (GM-CSF)-producing vaccines in-
duces rejection of subcutaneous and metastatic tumors accom-
panied by autoimmune depigmentation. J Exp Med. 1999;190:
355-366.
6. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed
with whole tumor lysates mediate potent antitumor immuneresponses in vitro and in vivo. Proc Natl Acad Sci USA.
1998;95:9482-9487.
7. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll
D, Levitsky H. The central role of CD4() T cells in the
antitumor immune response. J Exp Med. 1998;188:2357-2368.
8. Strome SE, Chang AE, Shu S, Krauss JC. Secretion of both
IL-2 and IL-4 by tumor cells results in rejection and immunity.
J Immunother. 1996;19:21-32.
9. Allan W, Tabi Z, Cleary A, Doherty PC. Cellular events in the
lymph node and lung of mice with inﬂuenza. Consequences of
depleting CD4 T cells. J Immunol. 1990;144:3980-3986.
